CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Cephalon Inc. v. Actavis LLC

1:14-cv-00122

Overview

Case Number 1:14-cv-00122
Filing Date 2014-01-31
Status Terminated
Termination Date 2015-09-08
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Actavis Elizabeth LLC Operating Company

Represented By

1 Attorneys Listed

Benjamin J. Schladweiler

Greenberg Traurig, LLP

Tel: +1 (302) 661-7394

The Nemours Building, 1007 North Orange Street, Suite 1200

Actavis LLC Operating Company

Represented By

6 Attorneys Listed

Vincent L. Capuano

Email: vcapuano@duanemorris.com

Laura A. Vogel

Email: lavogel@duanemorris.com

Emily N. Winfield

UNDELIVERABLE EMAIL 8/23/2019

Carolyn A. Alenci

Email: caalenci@duanemorris.com

Anthony J. Fitzpatrick

Email: AJFitzpatrick@duanemorris.com

Benjamin J. Schladweiler

Greenberg Traurig, LLP

Tel: +1 (302) 661-7394

The Nemours Building, 1007 North Orange Street, Suite 1200

Plaintiff

Cephalon Inc. Operating Company

Represented By

10 Attorneys Listed

Stephanie E. O'Byrne

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6067

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Nicholas K. Mitrokostas

Email: nicholas.mitrokostas@allenovery.com

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Jonathan A. Auerbach

UNDELIVERABLE EMAIL 9/28/2016

Emily L. Rapalino

Email: erapalino@goodwinlaw.com

David M. Hashmall

Email: dhashmall@goodwinlaw.com

David M. Fry

JPMorgan Chase & Co.

Tel: +1 (302) 455-3374

JPMorgan Chase & Co., 4041 Ogletown Stanton Road

Daryl L. Wiesen

Email: dwiesen@goodwinlaw.com

Calvin E. Wingfield , Jr.

Email: cwingfield@goodwinlaw.com

John W. Shaw

Shaw Keller LLP

Tel: +1 (302) 298-0701

I.M. Pei Building, 1105 North Market Street

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 10 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 1 proceeding
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (10): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (1 found):
PTAB: 1
USPTO PTAB Trial 2014-12-24
IPR2015-00503

AGILA SPECIALTIES INC. v. Cephalon, Inc.

U.S. Continuation Sibling (8436190)
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8445524
Solid forms of bendamustine hydrochloride
Filed: 2011-11-22
Issued: 2013-05-21
Active (5.0 yrs remaining)
Expires: 2031-11-22
US8436190
Bendamustine pharmaceutical compositions
Filed: 2006-01-12
Issued: 2013-05-07
Active (3.9 yrs remaining) +1748d PTA
Expires: 2030-10-26

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

1

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Procedural / Extension Motion 2 Claim Construction / Markman Filing 2 Motion to Dismiss 1

Key Dispositive Motions & Rulings

Motion to Dismiss Pending
Remark : Cases are consolidated for all purposes. All future filings shall be made only in lead CA 13-2046 GMS, including documents relating to the pending Moti...
Entry #— • 2014-11-24
Claim Construction / Markman Filing Pending
SO ORDERED - Proposed Scheduling Order filed by Cephalon, Inc. Setting Scheduling Order Deadlines: Cases are consolidated for all purposes. All future filings s...
Entry #— • 2014-11-24
Claim Construction / Markman Filing Pending
Minute Entry for proceedings held before Judge Gregory M. Sleet - Scheduling Conference held on 10/30/2014. These cases are consolidated for all purposes. Couns...
Entry #— • 2014-10-31
Procedural / Extension Motion Pending / Under Review
Joint STIPULATION TO EXTEND TIME for Defendants to move, answer or otherwise respond to Plaintiff's Complaint to March 28, 2014 - filed by Actavis Elizabeth LLC...
Entry #9 • 2014-02-21 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 9 Joint STIPULATION TO EXTEND TIME for Defendants to move, answer or otherwise respond to Plaintiff's Complaint to March 28, 2014 filed by Actavi...
Entry #— • 2014-02-21

Docket Entries

(65 total)
Pleading / Complaint

COMPLAINT filed against Actavis Elizabeth LLC, Actavis LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1452273.) - filed by Cephalon Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(dmp, ) (Entered: 02/03/2014)

Entry #1 • 2014-01-31
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 02/03/2014)

Entry #2 • 2014-01-31
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 01/02/2014. Date of Expiration of Patent: 03/26/2029.Thirty Month Stay Deadline: 7/2/2016. (dmp, ) (Entered: 02/03/2014)

Entry #3 • 2014-01-31
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,445,524 B2; US 8,436,190 B2;. (dmp, ) (Entered: 02/03/2014)

Entry #4 • 2014-01-31
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceuticals Industries Ltd. for Cephalon Inc. filed by Cephalon Inc.. (dmp, ) (Entered: 02/03/2014)

Entry #5 • 2014-01-31
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc